Resverlogix Company Description

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs.

It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.

Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada.

The company is headquartered in Calgary, Canada.

Resverlogix Corp.

Country	United States
Industry	Biotechnology
Sector	Healthcare
CEO	Donald McCaffrey

Contact Details

Address: 4820 Richard Road SW Calgary, Alberta Alberta Canada
Phone	403 254 9252

Stock Details

Ticker Symbol	RVXCF
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	CA76128M1086
SIC Code	2836

Key Executives

Name	Position
Donald J. McCaffrey	Co-Founder, Chairman, President, Chief Executive Officer and Secretary
Aaron Bradley Cann C.A., CPA, CBV	Chief Financial Officer
Dr. Ewelina Kulikowski Ph.D.	Chief Scientific Officer
Dr. Michael Sweeney M.D.	Senior Vice President of Clinical Development